AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
_6ff029a61766633234293.png?format=webp&width=1186&height=250)
Three Healthcare Stocks to Avoid: CooperCompanies, U.S. Physical Therapy, and Illumina
ByAinvest
Friday, Sep 26, 2025 3:49 am ET1min read
The healthcare industry has tumbled 1.4% over the past six months, lagging the S&P 500's 15.7% gain. CooperCompanies, U.S. Physical Therapy, and Illumina are three healthcare stocks to avoid. CooperCompanies has unexciting sales trends and declining free cash flow margin, while U.S. Physical Therapy has subscale operations and a declining free cash flow margin. Illumina's valuation ratio is high at 31.8x forward P/E.
Healthcare stocks in India experienced a significant downturn on Thursday following U.S. President Donald Trump's announcement of a 100% tariff on branded and patented drugs starting October 1. The move, which exempts only those manufacturers with U.S. plants under construction or recently broken ground, has sent ripples through the industry, with the Nifty Healthcare index falling by 1.2% [1].The impact of the tariffs varies among companies. Gland Pharma, which lacks a U.S. manufacturing footprint and relies heavily on branded or patented formulations, is particularly exposed. In contrast, companies like Syngene International, Piramal Pharma, and Zydus Lifesciences, which have contract manufacturing models and biologics portfolios, are less affected. Meanwhile, companies with large branded generics or biosimilars presence, such as Dr. Reddy’s Laboratories and Biocon, will need to accelerate U.S. production to avoid margin erosion [1].
Trump's announcement builds on his ongoing trade measures aimed at repatriating drug manufacturing. The latest rules extend to prescription medicines, biologics, specialty drugs, and over-the-counter products, while generic drugs remain exempt. The tariffs are part of a phased plan that began with a small tariff and will increase to 150% within 18 months and ultimately to 250% [1].
Retail sentiment on platforms like Stocktwits reflects the uncertainty. Gland Pharma, Syngene International, Piramal Pharma, Zydus Lifesciences, Dr. Reddy’s Laboratories, and Biocon have seen varied performances this year, with Gland Pharma up 6.5% and Syngene International down 29.1% [1].
In a separate development, FTAI Aviation reported a standout quarter with a 52.4% year-on-year revenue increase, generating over US$400 million in positive adjusted free cash flow. The company's continued dividend payouts underscore confidence in present cash flows [2].
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet